Trans-NIH Mouse Initiative
* Reports and Publications


OncoMouse® Agreement

The National Institutes of Health (NIH) and E.I. DuPont (DuPont) have signed an agreement on the use of DuPont's proprietary OncoMouse® transgenic animal technology covered by the Harvard "Leder" patents. The Memorandum of Understanding (MOU) describes the terms by which the technology can be used in research conducted by and/or supported by NIH, without compromising DuPont's ability to receive appropriate value from commercial applications of the technology. This agreement reinforces the partnership between NIH and DuPont first established over a year ago with the signing of the landmark agreement on Cre-lox technology. The full text of the Memorandum of Understanding is available at: